Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for non–small cell lung cancer (NSCLC).
Data from the EMPOWER-Lung 1 trial of cemiplimab (Libtayo) monotherapy vs platinum-based doublet chemotherapy show why the fully-human monoclonal antibody could become a new treatment option for first-line locally advanced or metastatic non–small cell lung cancer (NSCLC), especially for tumors with PD-L1 expression of at least 50%, according to a late-breaking abstract presented at this year’s virtual European Society for Medical Oncology (ESMO) meeting.
“In new analyses presented at ESMO, Libtayo reduced the risk of death by 43% in patients whose cancer had confirmed PD-L1 expression of 50% or greater. This is notable given that nearly three-quarters of patients crossed over from chemotherapy following disease progression and 12% of patients had pretreated and stable brain metastases,” Ahmet Sezer, MD, associate professor in the Department of Medical Oncology at Başkent University in Adana, Turkey, and a trial investigator, said in a statement.
In the open-label, multicenter, phase 3 trial, the 710 study participants were almost equally randomized into 2 groups: cemiplimab (n = 356) and investigator’s choice of chemotherapy (n = 354). Both groups had the same median follow-up of 13 months and range of follow-up, at <1 to 32 months. Overall survival (OS) and progression-free survival (PFS) were the primary end points, with overall response rate, duration of response, and quality of life being the secondary end points.
The overall results demonstrate cemiplimab’s superiority on several fronts compared with chemotherapy:
Cemiplimab’s benefit carried over into the 563 patients (cemiplimab group, n = 283; chemotherapy group, n = 280) with confirmed PD-L1 expression of at least 50%. Both groups again had the same 11-month median follow-up, with almost equal ranges: <1 to 32 months and <1 to 30 months, respectively. Results in this group demonstrated the following:
The PD-L1 IHC 22C3 pharmDx was used to confirm PD-L1 expression.
Treatment in the trial consisted of 350-mg intravenous (IV) cemiplimab every 3 weeks, for a maximum of 108 weeks, or investigator’s choice of standard-of-care chemotherapy for 4 to 6 cycles (with or without histology-relevant maintenance pemetrexed chemotherapy).
Importantly, objective response rate to cemiplimab was highest in tumors with at least 90% PD-L1 expression: 46% (range, 36%-56%). These tumors shrunk more than 40% after an average 6 months of treatment. Similar findings were not seen with chemotherapy.
The cemiplimab-treated patients also experienced 32% fewer grade 3 adverse events (AEs) overall: 37% vs 49% of patients receiving chemotherapy. The most common immune-mediated AEs, which occurred in 17% of patients receiving cemiplimab, were hypothyroidism (6%), hyperthyroidism (4%), pneumonitis (2%), hepatitis (2%), skin adverse reaction (2%), and arthritis, increased blood thyroid stimulating hormone, thyroiditis, colitis, nephritis, and peripheral neuropathy (each 1%).
Crossover was allowed from the chemotherapy to the cemiplimab arm, and occurred with 73.9%, and those receiving cemiplimab could combine it with 4 to 6 cycles of chemotherapy.
Cemiplimab already holds indications in the United States, European Union, and other countries for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in adults for whom curative surgery or radiation are not treatment options.
Reference
Sezer A, Kilickap S, Gümüş M, et al. EMPOWER-Lung 1: phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Presented at: European Society for Medical Oncology Virtual Congress 2020; September 19-21, 2020. Abstract LBA-52.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More